Send to

Choose Destination
Hematol Oncol Clin North Am. 2008 Dec;22(6):1267-78, x. doi: 10.1016/j.hoc.2008.08.012.

Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer.

Author information

Department of Clinical Oncology, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR.


Despite being potentially curable at an early stage, more than 50% of patients who have nasopharyngeal carcinoma present with advanced locoregional disease, which results in a poor prognosis. This article discusses key advancements in the management of nasopharyngeal cancer, including the incorporation of concurrent chemoradiotherapy, new radiotherapy delivery techniques in the form of conformal and intensity-modulated radiotherapy, and salvage options for locoregional recurrence. New cytotoxic and targeted therapies that have resulted in improved survival in the metastatic setting are also described. The use of Epstein-Barr virus DNA for the prognostication and monitoring of nasopharyngeal cancer and the role of new diagnostic imaging techniques are also discussed.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center